Neurovance, Inc. Company Profile
Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.
A Series A1 funding round has pulled in an additional $5.5 million for Neurovance. -More-
Three's company Neurovance Inc. Cambridge, Mass. Technology: Triple reuptake inhibitor for ADHD Disease focus: Neurology Clinical status: Phase II Founded: 2012 by Anthony McKinney, Frank Bymaster, Ga...
Neurovance (Cambridge, MA), a clinical stage pharmaceutical company developing a norepinephrine, dopamine and serotonin triple uptake inhibitor to treat ADHD, closed a $7M Series A financing. Particip...
—Recent Trials Provide Evidence of Both Efficacy and Reduced Abuse Liability— —Full Results of the Human Abuse Liability Study Presented at the American Coll...
Drugs and Medications
Neurovance is a neuroscience-focused, clinical-stage biopharmaceutical company that specializes in triple reuptake inhibitors specifically optimized for adult attention deficit hy...
Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurov...
More Information about "Neurovance, Inc." on BioPortfolio
We have published hundreds of Neurovance, Inc. news stories on BioPortfolio along with dozens of Neurovance, Inc. Clinical Trials and PubMed Articles about Neurovance, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neurovance, Inc. Companies in our database. You can also find out about relevant Neurovance, Inc. Drugs and Medications on this site too.